Burning Rock Biotech Announces Financial Results for Q2 2024
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), a frontrunner in utilizing next generation sequencing (NGS) technology for precision oncology, has released its financial results for the quarter ending June 30, 2024.
Recent Business Developments
The company has achieved significant progress in its business operations recently:
Therapy Selection
At a recent industry conference, Burning Rock shared important study findings related to small-cell lung cancer and colorectal cancer. These studies highlighted the efficacy and safety of high-dose Almonertinib for patients with untreated EGFR-mutated NSCLC and brain metastases.
Pharma Services
Moreover, the company announced a new partnership with Bayer aimed at developing companion diagnostics (CDx) for the Chinese market, which will enhance its capabilities and reach in precision medicine.
Financial Performance for Q2 2024
For the second quarter of 2024, Burning Rock reported total revenues of RMB135.5 million (approximately US$18.7 million), representing a 7.3% decrease from RMB146.3 million during the same period in 2023. This decline is largely attributed to the company's ongoing shift from central laboratory testing to more in-hospital testing solutions, despite seeing significant double-digit growth in the in-hospital segment.
- Revenue from the in-hospital business rose to RMB59.9 million (US$8.2 million), an increase of 11.2% compared to RMB53.8 million in Q2 2023, driven by higher sales volume.
- In contrast, central laboratory revenue decreased significantly to RMB48.8 million (US$6.7 million), down 26.4% from RMB66.2 million year-over-year, primarily due to a reduction in the number of tests conducted.
- Revenue from pharma research and development services saw a slight uptick to RMB26.9 million (US$3.7 million), a 2.6% increase from RMB26.2 million in 2023, fueled by growing demand from pharmaceutical clients.
In Q2 2024, the cost of revenues was RMB40.1 million (US$5.5 million), reflecting a 12.5% decrease from RMB45.8 million in Q2 2023. This reduction is mainly due to lower costs associated with central laboratory services and decreased amortization expenses across all business segments.
The gross profit for the quarter was RMB95.4 million (US$13.1 million), down 5.0% from RMB100.4 million in the previous year, with the gross margin slightly improving to 70.4% from 68.7% in 2023.
Excluding depreciation and amortization, the non-GAAP gross profit totaled RMB101.9 million (US$14.0 million), showing a 6.8% decline from RMB109.4 million year-on-year, with a corresponding non-GAAP gross margin of 75.2%.
Operating Expenses and Net Loss Overview
Operating expenses for the three-month period decreased to RMB206.7 million (US$28.4 million), a 12.5% reduction from RMB236.1 million in Q2 2023. This decline is primarily due to strict budget controls and workforce reductions aimed at improving operational efficiency.
- Research and development expenses dropped significantly by 32.2% to RMB65.0 million (US$8.9 million) from RMB95.8 million, mainly due to workforce adjustments and lower project spending.
- Selling and marketing expenses decreased by 31.0% to RMB48.9 million (US$6.7 million) from RMB70.8 million, attributed to reduced staffing costs and cuts in travel and conference expenditures.
- Conversely, general and administrative expenses rose by 33.5% to RMB92.8 million (US$12.8 million) from RMB69.5 million, primarily due to increased share-based compensation expenses.
The company reported a net loss of RMB108.0 million (US$14.9 million) for the second quarter, which is an improvement compared to the net loss of RMB131.2 million in the same quarter of 2023.
As of June 30, 2024, Burning Rock maintained a strong liquidity position, with cash, cash equivalents, restricted cash, and short-term investments totaling RMB533.0 million (US$73.3 million).
About Burning Rock Biotech Limited
Burning Rock Biotech Limited is dedicated to advancing precision oncology through innovative NGS technology. The company focuses on therapy selection testing for late-stage cancer patients and early cancer detection, which is currently in the clinical validation stages.
For additional information about Burning Rock, please reach out to their investor relations team via email at IR@brbiotech.com.
Frequently Asked Questions
What are the key financial highlights from Q2 2024?
Burning Rock reported total revenues of RMB135.5 million, which represents a 7.3% decline compared to the previous year. However, the in-hospital channel demonstrated encouraging growth, with an increase of 11.2% in revenue.
How did the transition from central-lab to in-hospital testing affect revenues?
This transition led to a 26.4% drop in central lab revenues, but it positively impacted the in-hospital business, which continued to experience significant growth.
What operational efficiencies were implemented?
Burning Rock has implemented strict budget controls and reduced its workforce to streamline operations and lower operating expenses, resulting in a 12.5% decrease in overall costs.
What was the net loss for the quarter, and how does it compare to the previous year?
The net loss for Q2 2024 was RMB108.0 million, showing improvement compared to the loss of RMB131.2 million reported in Q2 2023.
How much cash does Burning Rock have on hand?
As of the end of June 2024, the company has cash and cash equivalents totaling RMB533.0 million (US$73.3 million), ensuring a solid liquidity position to support its ongoing operations.
